
Elixiron Immunotherapeutics is a clinical-stage biotech company dedicated to developing precision immunotherapies for Alzheimer’s disease and vitiligo. Leveraging decades of immunology expertise and drug discovery experience, Elixiron has advanced two potential blockbuster drugs into clinical development, which include Enrupatinib for treating Alzheimer’s disease and Indemakitug for vitiligo. The company is a two-time winner of Alzheimer’s Association Part the Cloud awards and has secured two out-licensing agreements. Elixiron is seeking additional capital to accelerate the clinical development of Enrupatinib and Indemakitug for patients in need.
Address
CambridgeMassachusetts
United States